Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848847 | 0.83 | TDP1 (0.36) | TDP1SMN1; SMN2SLC22A6FFAR3HSPD1 | |
| SCHEMBL14620834 | 0.82 | TDP1 (0.39) | TDP1SMN1; SMN2SLC22A6FFAR3HSPD1 | |
| SCHEMBL27573194 | 0.81 | CA2 (0.38) | TDP1FFAR3HSPD1BLMHSPE1 | |
| SCHEMBL24401338 | 0.79 | GPR84 (0.40) | HSPD1BLMHSPE1GPR84 | |
| SCHEMBL7119137 | 0.79 | PGD (0.33) | SLC22A6PGD | |
| SCHEMBL7119132 | 0.79 | TSHR (0.31) | — | |
| SCHEMBL17376894 | 0.78 | TDP1 (0.36) | TDP1SMN1; SMN2SLC22A6FFAR3HSPD1 | |
| SCHEMBL27368103 | 0.78 | TDP1 (0.36) | TDP1SMN1; SMN2SLC22A6FFAR3HSPD1 | |
| SCHEMBL23964029 | 0.78 | TDP1 (0.36) | TDP1SMN1; SMN2SLC22A6PGDFOLH1 | |
| SCHEMBL8853350 | 0.78 | TDP1 (0.43) | TDP1SMN1; SMN2SLC22A6HSPD1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310616-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-1152014-B1 | RESIN COMPOSITION | MITSUBISHI RAYON CO (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-6552130-B1 | Used as a covering material for civil engineering and construction applications | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-1152014-A1 | RESIN COMPOSITION | Mitsubishi Rayon Co., Ltd. (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310616-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, IAPP | TDP1 1907/4885SMN1; SMN2 1381/4885SLC22A6 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.